Use of the human LRP/MVP promotor for a vector that can be...

Details Use of the human LRP/MVP promotor for a vector that can be... Use of the human LRP/MVP promotor for a vector that can be...

2007-11-20

2007-11-20

Sullivan, Daniel M. (Department: 1636)

Chemistry: molecular biology and microbiology

Vector, per se

C536S024100, C514S04400A

Reexamination Certificate

active

10416209

ABSTRACT:
Embodiments of the invention relate to a vector system that allows one to induce expression of therapeutically relevant genes in mammalian cells. Such a vector system may be useful for medicine and in the pharmaceutical industry. A vector comprises base structures suitable for expression in mammalian cells as well as either the whole of or parts of the gene promoter of human Major Vault Protein (MVP), also known as LRP (Lung Resistance Protein) as well as a gene encoding a therapeutic protein or non-translated RNA. As the MVP promoter is inducible by therapy (for example, but not limited to, chemotherapy or hyperthermia), the vector system provides combinations of therapeutic methods with gene therapy in a controlled fashion, resulting in more efficient treatment of tumor diseases.

REFERENCES:
patent: 5968735 (1999-10-01), Stein et al.
patent: 0 657 539 (1995-06-01), None
Pietrzkowski et al. (1991)) Exp. Cell Res. 193:283-290.
Chan et al. (2001) Plant Mol. Biol. 46 :131-141.
Omilli et al. (1986) Mol. Cell Biol. 6:1875-1885.
Arnone et al. (1997) Development 124:1851-1864.
Verma et al. (1997) Nature 389:239-242.
Marshall (1995) Science 269:1050-1055.
Orkin et al. (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy, available at http://www.nih.gov
ews/panelrep.html.
Eck et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 5, McGraw-Hill, NY.
Ross et al. (1996) Human gene Therapy 7:1781-1790.
Rubanyi (2001) Mol. Aspects Med. 22:113-142.
Gomez-Navarro et al. (2002) From: Mol. Basis Hum. Cancer (W.B. Coleman and G.J. Tsongalis, eds.), Humana Press Inc., Totowa, NJ, pp. 541-556.
Gottesman (2002) Cancer Gene Ther. 10:501-508.
C. Lange, Biochemical and Biophysical Research Communications, 278, 125-133 (2000) ; XP-002208365.
Doe Joint Genome Inst., “Sequencing of Human Chromosome 16”, XP-002208366, EMBL Accession No.: AC009133; Jul. 5, 2002.
U. Stein, “Homo sapiensMVP Gene, Promoter Region”, EMBL Accession No.: AJ238509, Dec. 1, 2000; XP-0022083667.
G. Scheffer et al., Nature Medicine, vol. 1, No. 6, Jun. 1995, pp. 578-582, XP-002002543.
W. Walther et al., Molecular Biotechnology, vol. 6, 1996, pp. 267-286.
W. Walther et al., Drugs, Aug. 2000, 60 (2), pp. 249-271.
S. Li et al., Gene Therapy (2000) 7, pp. 31-34.

Affiliated with

Also associated with

Rating

Use of the human LRP/MVP promotor for a vector that can be... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of the human LRP/MVP promotor for a vector that can be..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the human LRP/MVP promotor for a vector that can be... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3878801